HPA-Axis Dysregulation in Depression

The hypothesis and why it matters

If any biological abnormality has a claim to being the signature finding of depression, it is dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis — the body's central stress-response system. HPA hyperactivity, hypercortisolemia, and impaired feedback regulation are among the most replicated biological findings in all of psychiatry, present in a substantial subset of depressed patients (particularly the severe and melancholic), and the stress hypothesis holds that chronic dysregulation of this system — too much cortisol, for too long, with the normal "off switch" broken — is a central driver of depression: damaging the brain regions that regulate mood, disrupting neuroplasticity, and feeding the inflammatory and metabolic cascades that constitute the broader web of depression's biology.

This matters for three reasons. First, it provides the clearest biological bridge between life stress and brain pathology — the HPA axis is precisely the system through which psychological stress becomes a physiological, brain-altering force, making it the mechanistic heart of the stress-causes-depression intuition. Second, it has produced the most established structural finding in depression — stress-related hippocampal damage. Third, and instructively, it is a cautionary tale: despite being the strongest neuroendocrine association in the field, attempts to treat depression by directly targeting the HPA axis have largely failed — a humbling demonstration (echoing the serotonin and inflammation stories) that a powerful association does not guarantee a therapeutic target.

The honest framing: HPA dysregulation is the most robustly established neuroendocrine abnormality in depression, mechanistically central, the clearest link between stress and the depressed brain, and the foundation of the developmental (early-adversity) model of vulnerability — yet it is present in a subset rather than universally, is partly a consequence as well as a cause, and has stubbornly resisted becoming a direct treatment target.

The HPA axis: how the stress system works

The HPA axis is an elegant, self-regulating cascade:

• The hypothalamus, sensing stress, releases corticotropin-releasing hormone (CRH).
• CRH stimulates the pituitary to release adrenocorticotropic hormone (ACTH).
• ACTH stimulates the adrenal glands to release cortisol, the principal stress hormone.
• Cortisol mobilizes energy, modulates immunity, and acts on the brain and body to manage the stressor — and then, crucially, feeds back on the hypothalamus, pituitary, and (importantly) the hippocampus, binding glucocorticoid receptors (GRs) to shut the axis off. This negative feedback is what makes the stress response self-limiting: cortisol rises, does its job, and switches off its own production.

Cortisol also follows a strong circadian rhythm (high in the morning, low at night — linking to the sleep/circadian document), and the system is built for acute stress: mobilize, respond, recover. The pathology of depression is what happens when this acute, self-limiting system becomes chronically activated and loses its off switch.

The evidence: the most replicated neuroendocrine finding in depression

The HPA abnormalities in depression are among psychiatry's most consistent biological findings:

• Hypercortisolemia. A substantial proportion of depressed patients — especially those with severe and melancholic depression — show elevated cortisol (raised levels, increased daily output, flattened diurnal rhythm).
• Dexamethasone suppression test (DST) non-suppression. The classic demonstration: dexamethasone, a synthetic glucocorticoid, normally suppresses cortisol production by triggering negative feedback. In a significant fraction of depressed patients — again concentrated in melancholic and psychotic depression — dexamethasone fails to suppress cortisol (DST non-suppression), revealing impaired negative feedback: the axis cannot be switched off normally. The DST was once explored as a diagnostic test for depression; it proved insufficiently specific for that, but it robustly demonstrated the feedback abnormality. The combined dexamethasone/CRH test is even more sensitive in revealing the dysregulation.
• Elevated CRH. Increased CRH activity (including elevated CRH in cerebrospinal fluid) points to overdrive at the top of the axis.
• Normalization with recovery. HPA abnormalities tend to normalize as depression remits, and persistent HPA dysregulation after apparent recovery predicts relapse — suggesting the abnormality tracks (and may drive) the illness state.
• The natural experiments. Two confirm causality in the cortisol-to-depression direction: Cushing's syndrome (pathological cortisol excess) causes depression in a large fraction of patients, reversible when the cortisol excess is corrected; and exogenous corticosteroids (prescribed for medical conditions) reliably cause mood disturbances — depression, but also mania, anxiety, and psychosis — demonstrating that cortisol excess can directly produce psychiatric illness.

The central mechanism: glucocorticoid resistance

The key to understanding HPA dysregulation in depression is not simply "too much cortisol" but broken feedback — and its molecular basis is glucocorticoid receptor (GR) resistance.

Normally, rising cortisol binds GRs and shuts the axis off. In depression, the GRs become less responsive — the tissues, including the brain regions mediating feedback, stop "hearing" cortisol's off-signal. The result is a paradox: cortisol is high, yet the body behaves as though it is functionally insufficient at the receptor level — the axis keeps running because the brake doesn't engage. This glucocorticoid resistance explains how the system can be simultaneously over-active (high cortisol) and under-regulated (failed feedback), and it has profound downstream consequences:

• It perpetuates the chronic cortisol elevation (no off-switch).
• It unleashes inflammation: cortisol is normally anti-inflammatory, restraining the immune system; when immune cells become glucocorticoid-resistant, inflammation runs unchecked despite high cortisol — a direct molecular bridge to the inflammatory hypothesis (the inflammation document), and one reason inflammation and HPA dysregulation co-occur.
• The molecular machinery of GR resistance — including the gene FKBP5, which regulates GR sensitivity and is a key node in the gene-environment interaction with early stress (below) — has become a central focus of stress-biology research.

How HPA dysregulation damages the brain and produces depression

Chronic cortisol elevation, via glucocorticoid resistance, produces depression through several well-characterized routes:

Hippocampal damage — the signature structural finding. The hippocampus is densely populated with glucocorticoid receptors and is a key site of HPA negative feedback — and it is exquisitely vulnerable to chronic cortisol. Sustained cortisol elevation causes dendritic atrophy, suppressed neurogenesis, and ultimately hippocampal volume loss — and reduced hippocampal volume is one of the most replicated structural abnormalities in depression (Sheline, Sapolsky, and others), correlating with illness duration. This creates a vicious cycle: cortisol damages the hippocampus, and the damaged hippocampus is less able to provide the negative feedback that shuts off cortisol — so the dysregulation worsens itself. The hippocampal mechanism is the clearest demonstration in psychiatry of stress producing measurable brain damage.

Prefrontal and amygdala effects. Chronic stress and cortisol impair the prefrontal cortex (degrading top-down emotional regulation and executive function) while hypertrophying the amygdala (heightening threat reactivity and anxiety) — shifting the brain toward a more reactive, less regulated, threat-dominated state characteristic of depression and anxiety.

Impaired neuroplasticity and BDNF. Cortisol suppresses BDNF and the neuroplastic and neurogenic processes central to mood regulation and antidepressant action — connecting HPA dysregulation to the plasticity hub of this series. (Antidepressants, conversely, increase BDNF and normalize HPA function over weeks, possibly part of their mechanism.)

Metabolic effects. Cortisol is a glucose-raising, fat-redistributing hormone; chronic elevation promotes insulin resistance and visceral fat deposition (the metabolic document) — making the HPA axis a shared driver of depression and metabolic dysfunction.

Inflammatory effects. Via glucocorticoid resistance (above), HPA dysregulation unleashes inflammation — tying it to the inflammatory cascade.

So a single upstream abnormality — chronic, poorly-regulated cortisol elevation — radiates outward into hippocampal damage, prefrontal/amygdala dysfunction, impaired plasticity, metabolic dysfunction, and inflammation, converging on the depressive phenotype from several directions at once.

The developmental story: early adversity and programmed vulnerability

Among the most important contributions of HPA research is the explanation it provides for why early-life adversity is such a powerful risk factor for adult depression — arguably the single most robust environmental risk factor in psychiatry.

Early stress programs the HPA axis. Adverse experiences in early life — abuse, neglect, severe early stress — produce lasting dysregulation of the HPA axis, recalibrating the stress-response system toward a hyperreactive, poorly-regulated set point that persists into adulthood and confers vulnerability to depression. The developing stress system is "programmed" by early experience, and adversity programs it toward dysregulation.

The epigenetic mechanism. The landmark work (Michael Meaney, Moshe Szyf, and colleagues, originally in rodents and extended to humans) showed that early caregiving experience produces epigenetic modifications — notably DNA methylation of the glucocorticoid receptor gene — that durably alter GR expression and thus HPA reactivity, in a way transmitted across the lifespan (and potentially across generations). Low early care → altered GR methylation → fewer GRs → impaired feedback → a more reactive, dysregulated stress axis → lifelong vulnerability. The FKBP5 gene provides a parallel gene-environment story: certain FKBP5 variants, interacting with early trauma, produce lasting GR resistance and elevated depression and PTSD risk — a model case of how genes and early environment jointly shape the stress system.

This developmental account is one of the most important in biological psychiatry: it provides a concrete, molecular mechanism for how early experience becomes lasting biological vulnerability, explains the potency of childhood adversity as a depression risk factor, and grounds the intuition that stress "gets under the skin" in specific, measurable epigenetic and neuroendocrine changes.

Subtypes and clinical correlates

The HPA contribution is not uniform across depression, and the heterogeneity is informative:

• Melancholic depression — classically associated with HPA hyperactivity and hypercortisolemia (DST non-suppression, elevated cortisol). The melancholic patient — with anhedonia, psychomotor disturbance, early-morning awakening, diurnal mood variation (worse in the morning, when cortisol peaks), weight loss — fits the high-cortisol, high-CRH profile.
• Atypical depression — intriguingly, may be associated with the opposite — relatively low CRH/HPA activity (hypocortisolemia) — with its hypersomnia, hyperphagia, leaden fatigue, and reactivity representing a different (and overlapping with the immunometabolic) neuroendocrine profile. This melancholic-hypercortisolemic versus atypical-hypocortisolemic distinction is one of the more important subtype findings in the field.
• Psychotic depression — among the most strongly hypercortisolemic, with the highest rates of DST non-suppression — and notably the subtype where antiglucocorticoid treatment showed its clearest (if modest) signal.
• Severity and chronicity — HPA dysregulation tracks with severity, and persistent dysregulation predicts relapse.

Treatment implications — and the humbling failure

The HPA model generates an obvious treatment logic — if too much cortisol drives depression, block it — and the result is one of the most instructive disappointments in psychiatric pharmacology:

• Antiglucocorticoid and CRH-antagonist drugs largely failed. Despite the powerful association, drugs targeting the HPA axis have mostly not worked: CRH-receptor antagonists, developed with great hope, failed in depression trials; cortisol-synthesis inhibitors and the glucocorticoid-receptor antagonist mifepristone showed, at best, modest and inconsistent effects — with mifepristone's clearest (still limited) signal in psychotic depression, the most hypercortisolemic subtype. The broad failure of HPA-targeted treatment, despite the strongest neuroendocrine association in psychiatry, is a genuine cautionary tale: it demonstrates, like the serotonin and inflammation stories, that a robust biological correlate need not be a viable therapeutic target — the abnormality may be a marker, a consequence, or one node in a web too interconnected to fix by targeting a single point.
• What does work acts indirectly: antidepressants normalize HPA function over weeks (possibly part of their mechanism), psychotherapy and stress reduction address the upstream stressors, exercise modulates the stress response, and treating the downstream consequences (sleep, inflammation, metabolic) addresses the web the HPA axis feeds. The lesson is that the stress axis is better addressed by reducing the stress and supporting the systems it damages than by pharmacologically blocking the hormone.

The convergence

HPA dysregulation is one of the most central integrating nodes in depression's biology, radiating into nearly every other mechanism:

• Inflammation — glucocorticoid resistance unleashes inflammation; inflammation activates the HPA axis (bidirectional).
• Metabolic dysfunction — cortisol drives insulin resistance and visceral adiposity.
• Sleep — sleep loss activates the HPA axis; cortisol's circadian rhythm links the two; stress disrupts sleep.
• Mitochondrial — chronic stress/cortisol produces mitochondrial allostatic load (the mitochondrial document).
• Neuroplasticity — cortisol suppresses BDNF and damages the hippocampus, the structural heart of the plasticity story.
• Early adversity and genetics — the HPA axis is the system through which early environment and stress-related genes (FKBP5, GR) produce lasting vulnerability.

The HPA axis is, in a real sense, the mechanism through which psychological stress becomes biological depression — the bridge between the life events and adversity that precipitate depression and the brain pathology that constitutes it. It is where the psychosocial and the biological meet, which is why it radiates into every other mechanism and why "stress" is both a psychological and a precisely physiological concept.

The bottom line

HPA-axis dysregulation is the most robustly established neuroendocrine abnormality in depression — hypercortisolemia and impaired negative feedback (DST non-suppression), driven at the molecular level by glucocorticoid resistance, present especially in severe, melancholic, and psychotic depression, and confirmed as causal by the natural experiments of Cushing's syndrome and steroid-induced mood disorders. Its mechanisms are well-characterized and central: chronic cortisol elevation damages the hippocampus (the signature structural finding, in a self-worsening cycle since the damaged hippocampus can no longer regulate the axis), impairs the prefrontal cortex while sensitizing the amygdala, suppresses neuroplasticity and BDNF, and feeds the metabolic and inflammatory cascades — radiating from a single upstream abnormality into the whole web of depression biology. Its developmental dimension is among the most important in the field: early-life adversity epigenetically programs the HPA axis toward lasting dysregulation (the GR-methylation and FKBP5 gene-environment stories), providing a concrete molecular mechanism for how childhood adversity becomes adult vulnerability and grounding the intuition that stress "gets under the skin." And it offers a genuine cautionary lesson: despite being the strongest neuroendocrine association in psychiatry, the HPA axis resisted becoming a direct treatment target — antiglucocorticoid and CRH-antagonist drugs largely failed, demonstrating that a powerful biological correlate is not necessarily a therapeutic one, and that the stress axis is better addressed by reducing stress, supporting the damaged downstream systems, and the indirect HPA-normalizing effects of antidepressants, psychotherapy, and exercise. Most fundamentally, the HPA axis is the mechanism through which psychological stress becomes biological depression — the bridge between adversity and brain pathology, and the place where the psychosocial and biological models of depression are revealed to be describing the same thing from different angles.

Selected references

1. Holsboer, F. (2000). The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology, 23(5), 477–501.
2. Pariante, C.M., & Lightman, S.L. (2008). The HPA axis in major depression: Classical theories and new developments. Trends in Neurosciences, 31(9), 464–468.
3. Nemeroff, C.B. (1996). The corticotropin-releasing factor (CRF) hypothesis of depression: New findings and new directions. Molecular Psychiatry, 1(4), 336–342.
4. Carroll, B.J., et al. (1981). A specific laboratory test for the diagnosis of melancholia: The dexamethasone suppression test. Archives of General Psychiatry, 38(1), 15–22.
5. Sapolsky, R.M. (2000). Glucocorticoids and hippocampal atrophy in neuropsychiatric disorders. Archives of General Psychiatry, 57(10), 925–935.
6. Sheline, Y.I., Wang, P.W., Gado, M.H., Csernansky, J.G., & Vannier, M.W. (1996). Hippocampal atrophy in recurrent major depression. PNAS, 93(9), 3908–3913.
7. McEwen, B.S. (1998). Stress, adaptation, and disease: Allostasis and allostatic load. Annals of the New York Academy of Sciences, 840, 33–44.
8. Weaver, I.C.G., et al. (Meaney, M.J., Szyf, M.) (2004). Epigenetic programming by maternal behavior. Nature Neuroscience, 7(8), 847–854.
9. McGowan, P.O., et al. (2009). Epigenetic regulation of the glucocorticoid receptor in human brain associates with childhood abuse. Nature Neuroscience, 12(3), 342–348.
10. Binder, E.B., et al. (2008). Association of FKBP5 polymorphisms and childhood abuse with risk of PTSD symptoms in adults. JAMA, 299(11), 1291–1305.
11. Heim, C., & Nemeroff, C.B. (2001). The role of childhood trauma in the neurobiology of mood and anxiety disorders. Biological Psychiatry, 49(12), 1023–1039.
12. Pariante, C.M., & Miller, A.H. (2001). Glucocorticoid receptors in major depression: Relevance to pathophysiology and treatment. Biological Psychiatry, 49(5), 391–404.
13. Belanoff, J.K., et al. (2002). An open label trial of C-1073 (mifepristone) for psychotic major depression. Biological Psychiatry, 52(5), 386–392.
14. Holsboer, F., & Ising, M. (2010). Stress hormone regulation: Biological role and translation into therapy. Annual Review of Psychology, 61, 81–109.
15. Nandam, L.S., et al. (2020). Cortisol and major depressive disorder — translating findings from humans to animal models and back. Frontiers in Psychiatry, 10, 974.
16. Stetler, C., & Miller, G.E. (2011). Depression and hypothalamic-pituitary-adrenal activation: A quantitative summary of four decades of research. Psychosomatic Medicine, 73(2), 114–126.
17. Lupien, S.J., McEwen, B.S., Gunnar, M.R., & Heim, C. (2009). Effects of stress throughout the lifespan on the brain, behaviour and cognition. Nature Reviews Neuroscience, 10(6), 434–445.
18. Gold, P.W. (2015). The organization of the stress system and its dysregulation in depressive illness. Molecular Psychiatry, 20(1), 32–47.
19. Raison, C.L., & Miller, A.H. (2003). When not enough is too much: The role of insufficient glucocorticoid signaling in the pathophysiology of stress-related disorders. American Journal of Psychiatry, 160(9), 1554–1565.
20. Zorn, J.V., et al. (2017). Cortisol stress reactivity across psychiatric disorders: A systematic review and meta-analysis. Psychoneuroendocrinology, 77, 25–36.